Consun Pharmaceutical (HKG:1681) said it will expand its on-market share repurchase program to an aggregate cap of HK$300 million, following a board resolution, according to a Thursday Hong Kong bourse filing.
The company had previously approved a HK$200 million buyback in June 2025 and has now authorised a further HK$100 million under the existing shareholder-approved general mandate.
Consun said the repurchases will be funded from existing cash resources and conducted in the open market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments